Cassava Sciences, Inc.
Cassava Sciences, Inc. (SAVA) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
sava · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Cassava Sciences, Inc. (SAVA) measures how much investors pay for each dollar of the company's trailing earnings. SAVA's current PE ratio of N/A is calculated by dividing its stock price of $1.32 by its TTM earnings per share of -$1.61.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 4 fiscal years · Front-end computedMinQ1 · 25%2.8x
MedianQ3 · 75%9.1x
Max
At N/A, SAVA's current P/E is lower than in 0% of its annual fiscal year readings over the past 4 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Cassava Sciences, Inc.You SAVA | $64M | N/A | — | -$1.61 |
 Alector, Inc. ALEC | $182M | N/A | — | -$1.39 |
 Cardiff Oncology, Inc. CRDF | $103M | N/A | — | -$0.69 |
 Cybin Inc. CYBN | $413M | N/A | — | -$0.61 |
 Elicio Therapeutics, Inc. ELTX | $259M | N/A | — | -$2.58 |
 Fate Therapeutics, Inc. FATE | $223M | N/A | — | -$1.15 |
 Milestone Pharmaceuticals Inc. MIST | $106M | N/A | — | -$0.75 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-1.88 | — | |
2024-12-31 FY2024 | — | $-0.53 | — | |
2023-12-31 FY2023 | — | $-2.32 | — | |
2022-12-31 FY2022 | — | $-1.90 | — | |
2021-12-31 FY2021 | — | $-0.82 | — | |
2020-12-31 FY2020 | — | $-0.24 | — | |
2019-12-31 FY2019 | — | $-0.27 | — | |
2018-12-31 FY2018 | — | $-0.61 | — | |
2017-12-31 FY2017 | — | $-1.82 | — | |
2016-12-31 FY2016 | — | $-2.28 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Cassava Sciences, Inc. (SAVA) measures how much investors pay for each dollar of the company's trailing earnings. SAVA's current PE ratio of N/A is calculated by dividing its stock price of $1.32 by its TTM earnings per share of -$1.61.
Frequently asked questions
SAVA pe ratio · 6 questionsSAVA's current PE ratio is N/A as of 2026-06-09, based on a stock price of $1.32 and TTM EPS of -$1.61. Data sourced from Financial Modeling Prep via SAVA's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Cassava Sciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09